Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer
  2. Aide
  2. Aide
CAC 40
7 882,15
+1,22%
Indices
Chiffres-clés
+ fortes hausses et baisses SBF 120

All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
information fournie par Boursorama CP 10/05/2022 à 17:45

-­ TG4050 – New positive preliminary Phase I results presented at AACR 2022; additional clinical data to be presented at ASCO 2022
­
- BT-001 – Preclinical data presented at AACR 2022. Phase I clinical update to be released in Q2 2022

­- Dr. Alessandro Riva proposed as new independent Director and non-executive Chairman of the Board, separating the roles of Chairman and Chief Executive Officer

­- €46.8 million in cash and cash equivalents as of March 31, 2022 – Confirmed financial visibility until the end of 2023

.../...

Valeurs associées

TRANSGENE
1,2000 EUR Euronext Paris +4,80%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...

Pages les plus populaires

L'offre BoursoBank